VBIV

VBI Vaccines Inc. [VBIV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VBIV Stock Summary

Top 10 Correlated Stocks

VBIV


In the News

10:41 10 Jun 2023 VBIV

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

12:56 10 Jun 2023 VBIV

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

08:14 10 Jun 2023 VBIV

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.

10:44 10 Jun 2023 VBIV

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

12:48 10 Jun 2023 VBIV

VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

10:42 10 Jun 2023 VBIV

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The company's efforts in 2022 have fortified that position.

03:44 10 Jun 2023 VBIV

VBI Vaccines (VBIV) Stock: Why It Fell 10.72% After Hours

The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.

12:30 10 Jun 2023 VBIV

Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today

Healthcare has become a bona fide stock picker's market this year.

08:04 10 Jun 2023 VBIV

3 Biotech Penny Stocks That Climbed in After-Hours Trading

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:21 10 Jun 2023 VBIV

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperforming historical controls. VBI-1901 is showing its ability to have an impact on the tumor response and clinical outcomes. One patient who is still on protocol has been progression-free for over two years.

VBIV Financial details

Company Rating
Neutral
Market Cap
24.53M
Income
-152.73M
Revenue
1.44M
Book val./share
5.22
Cash/share
4.69
Dividend
-
Dividend %
-
Employees
190
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-0.19
Forward P/E
-
PEG
-0.02
P/S
16.61
P/B
0.53
P/C
0.59
P/FCF
-0.3
Quick Ratio
1.42
Current Ratio
1.75
Debt / Equity
1.85
LT Debt / Equity
1.14
-
-
EPS (TTM)
-15.53
EPS next Y
-
EPS next Q
-0.08
EPS this Y
-92.99%
EPS next Y
-
EPS next 5Y
-97.97%
EPS last 5Y
-10.91%
Revenue last 5Y
-20.25%
Revenue Q/Q
65.53%
EPS Q/Q
5610.53%
-
-
-
-
SMA20
-
SMA50
-62.5%
SMA100
-82.35%
Inst Own
36.03%
Inst Trans
-0.82%
ROA
-100%
ROE
-171%
ROC
-0.86%
Gross Margin
-738%
Oper. Margin
-5927%
Profit Margin
-8880%
Payout
-
Shs Outstand
8.61M
Shs Float
6.68M
-
-
-
-
Target Price
5
52W Range
2.35-40.5
52W High
-93.13%
52W Low
+37.5%
RSI
43
Rel Volume
0.27
Avg Volume
107.74K
Volume
28.67K
Perf Week
0.36%
Perf Month
-6.46%
Perf Quarter
-78.41%
Perf Half Y
-81.11%
-
-
-
-
Beta
1.82759
-
-
Volatility
0.16%, 0.19%
Prev Close
-1.08%
Price
2.75
Change
-4.84%

VBIV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.050.560.150.070
Net income per share
-0.98-15.1-6.11-7.85-0.55
Operating cash flow per share
-0.69-12.23-6.47-4.7-0.29
Free cash flow per share
-0.78-13.16-6.6-4.93-0.3
Cash per share
0.911.116.3714.320.24
Book value per share
1.4922.1723.616.930.25
Tangible book value per share
0.486.3514.759.360.01
Share holders equity per share
1.4922.1723.616.930.25
Interest debt per share
0.264.492.834.30.22
Market cap
3.15B164.84M600.24M596.58M3.03B
Enterprise value
3.11B135.47M507.36M506.68M3.02B
P/E ratio
-49.11-2.74-13.49-8.94-21.5
Price to sales ratio
939.2274.22565.73945.452.8K
POCF ratio
-69.2-3.38-12.76-14.95-41.12
PFCF ratio
-61.16-3.15-12.49-14.24-38.83
P/B Ratio
32.111.873.54.1547.23
PTB ratio
32.111.873.54.1547.23
EV to sales
925.7460.99478.19802.982.79K
Enterprise value over EBITDA
-52.42-2.94-11.63-7.45-36.91
EV to operating cash flow
-68.21-2.78-10.78-12.7-40.98
EV to free cash flow
-60.28-2.59-10.56-12.09-38.7
Earnings yield
-0.02-0.36-0.07-0.11-0.05
Free cash flow yield
-0.02-0.32-0.08-0.07-0.03
Debt to equity
0.40.380.220.461.42
Debt to assets
0.290.280.180.320.59
Net debt to EBITDA
0.760.642.131.320.13
Current ratio
2.641.587.6142.1
Interest coverage
-18.56-23.86-16.11-14.38-20.42
Income quality
0.720.891.020.570.65
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.26.3419.4660.7551.87
Research and developement to revenue
11.4711.86143114.33
Intangibles to total assets
0.480.520.310.310.39
Capex to operating cash flow
0.130.080.020.050.06
Capex to revenue
-1.79-1.65-0.94-3.16-4.01
Capex to depreciation
-11.06-3.05-0.61-1.09-2.11
Stock based compensation to revenue
0.991.774.9815.268.96
Graham number
5.7386.7856.9854.71.75
ROIC
-4.68-1.76-2.331.74-6.04
Return on tangible assets
-0.9-1.01-0.31-0.46-1.49
Graham Net
0.312.7511.356.66-0.1
Working capital
38.35M17.21M114.69M97.7M40.75M
Tangible asset value
31.62M25.29M107.29M79.53M3.69M
Net current asset value
22.26M13.02M94.37M63.89M-13.23M
Invested capital
0.140.180.10.220.81
Average receivables
99.5K128.5K139K42.5K51K
Average payables
3.93M3.59M2.43M4.01M8.63M
Average inventory
849.5K993K1.61M2.36M4.59M
Days sales outstanding
6.0933.0326.494.6331.71
Days payables outstanding
490.1552.04148.66145.05419.93
Days of inventory on hand
73.7449.6485.6887.3213.61
Receivables turnover
59.9111.0513.7878.8811.51
Payables turnover
0.747.012.462.520.87
Inventory turnover
4.957.354.264.181.71
ROE
-0.65-0.68-0.26-0.46-2.2
Capex per share
-0.09-0.92-0.14-0.23-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
0.010.040.0400.06
Net income per share
-2.98-7.85-3.26-0.08-4.34
Operating cash flow per share
-2.31-2.03-2.01-0.07-2.51
Free cash flow per share
-2.37-2.15-2.16-0.08-2.58
Cash per share
11.779.579.710.244.69
Book value per share
15.0512.269.740.255.22
Tangible book value per share
7.444.872.790.01-1.81
Share holders equity per share
15.0512.269.740.255.22
Interest debt per share
446.180.216.3
Market cap
428.71M208.8M182.28M3.03B78.33M
Enterprise value
360.76M159.73M150.63M3.02B90.31M
P/E ratio
-4.18-0.77-1.62-38.58-0.52
Price to sales ratio
3.4K603.47575.0110.34K161.51
POCF ratio
-21.52-11.97-10.55-159.1-3.62
PFCF ratio
-20.97-11.27-9.81-147.83-3.53
P/B Ratio
3.311.982.1747.231.74
PTB ratio
3.311.982.1747.231.74
EV to sales
2.86K461.64475.1810.31K186.2
Enterprise value over EBITDA
-23.47-7.2-7.33-148.95-4.88
EV to operating cash flow
-18.11-9.15-8.72-158.55-4.17
EV to free cash flow
-17.65-8.62-8.11-147.32-4.07
Earnings yield
-0.06-0.32-0.15-0.01-0.48
Free cash flow yield
-0.05-0.09-0.1-0.01-0.28
Debt to equity
0.50.631.051.421.85
Debt to assets
0.330.390.510.590.65
Net debt to EBITDA
4.422.211.540.51-0.65
Current ratio
3.312.292.772.11.75
Interest coverage
-15.65-21.21-16.95-11.57-10.1
Income quality
0.940.380.690.90.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
86.7543.644.8654.220
Research and developement to revenue
18.7516.3115.728.596.5
Intangibles to total assets
0.340.370.350.390.47
Capex to operating cash flow
0.030.060.080.080.02
Capex to revenue
-4.09-3.11-4.1-4.96-1.1
Capex to depreciation
-1.09-1.99-2.47-2.79-1.05
Stock based compensation to revenue
19.867.17.617.944.15
Graham number
31.7646.5426.730.6522.59
ROIC
1.53-19.743.55-1.18-0.7
Return on tangible assets
-0.2-0.62-0.25-0.21-0.55
Graham Net
4.772.290.01-0.08-4.47
Working capital
78.36M52.22M61.54M40.75M22.26M
Tangible asset value
64.04M41.94M23.99M3.69M-15.61M
Net current asset value
47.91M26.15M8.02M-13.23M-31.6M
Invested capital
0.260.320.620.811.16
Average receivables
2.16M2.66M2.47M3.3M2.81M
Average payables
4.1M4.77M8.64M12.32M11.41M
Average inventory
3.32M4.05M4.92M6.2M6.68M
Days sales outstanding
2.05K636.76704.671.27K275.38
Days payables outstanding
128.33200.45392.94350.83248.76
Days of inventory on hand
132.58144.53195.22178.46171.15
Receivables turnover
0.040.140.130.070.33
Payables turnover
0.70.450.230.260.36
Inventory turnover
0.680.620.460.50.53
ROE
-0.2-0.64-0.33-0.31-0.83
Capex per share
-0.06-0.13-0.15-0.01-0.06

VBIV Frequently Asked Questions

What is VBI Vaccines Inc. stock symbol ?

VBI Vaccines Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VBIV

What is VBI Vaccines Inc. stock quote today ?

VBI Vaccines Inc. stock price is $2.75 today.

Is VBI Vaccines Inc. stock public?

Yes, VBI Vaccines Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap